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Abstract              
Aims: Rigosertib (RGS) is a PI3K inhibitor that exerts protective effects against tumor progression 
and cancer-related inflammation. This study was aimed to explore the regulatory effects of RGS 
on proliferative, pro-fibrotic and inflammatory factors in DSS- induced colitis mice model. 
Materials and Methods: The present study integrates systems and molecular biology approaches 
to investigate the therapeutic potency of RGS in an experimental model of colitis specifically 
examining its effects on the PI3K/AKT and NF-κB signaling pathways.  
Key findings: Analysis of time-resolved proteome profiling showed that PI3K-AKT inhibitors 
regulate expression of many proteins in all stages of inflammation, fibrogenesis and extracellular 
matrix remodeling. Consistent with our in-silico findings, RGS improved colitis disease activity as 
assessed by changes in body weight, degree of stool consistency, rectal bleeding and prolapse. 
RGS also reduced oxidative stress markers and colon histopathological score by decreasing 
inflammatory responses in colon tissues. Moreover, expression of pro-fibrotic and pro-
inflammatory factors including Acta 2, Col 1a1, Col 1a2, IL-1β, TNF-α, INF-γ, and MCP-1 were 
suppressed in the mice treated with RGS compared to the control group. The protective effects 
of RGS were mediated by inactivation of PI3K/AKT and NF-kB signaling pathways.  
Significance: This study clearly demonstrates the anti-proliferative, anti-inflammatory and anti-
fibrotic effects of RGS in colitis, that may have implications for the treatment of colitis and colitis-
associated cancer. 










Ulcerative colitis (UC) is a common form of inflammatory bowel disease (IBD) with a high 
global prevalence [1, 2]. UC is characterized by chronic mucosal inflammation, from rectum to 
proximal segments of the colon [3, 4]. Colicky abdominal pain, bloody diarrhea, fatigue, fever, and 
weight loss are typical clinical symptoms in UC patients [5, 6]. Most of the current treatments for 
colitis target inflammatory and immune responses in patients [7]. However, these therapies are 
often time-consuming, and are associated with adverse effects. Patients with UC are at higher 
risk for developing colorectal cancer [8]. The main underlying cause in the development of colitis 
associated cancer (CAC) is chronic colon inflammation, resulting in activation of oncogenic 
signaling pathways and uncontrolled cellular proliferation in the intestinal lining [9-11].  
High-throughput data acquisition and systems-level approaches have provided a more 
holistic view of UC, but these have required computational methodologies to discover the novel 
targets that are amenable to drug intervention. In the light of the new findings, mucosal healing, 
that follows remission of inflammation, is increasingly being appreciated as being important in 
determining the efficacy of UC treatment, fewer remission of the disease and decreased risk of 
developing cancer [12]. Based on these insights, drugs that mimic the normal sequence of wound 
healing and resolution may serve as novel therapeutics for unresponsive and recurrent UC 
disease. 
Rigosertib (RGS) is a novel styryl benzyl sulfone with anti-tumor properties in different 
types of malignancy and is currently undergoing phase III clinical trials for the treatment of 
myelodysplastic syndrome (MDS) [13-17]. RGS has been shown to induce G2/M cell cycle arrest 
and apoptosis by down-regulating the Ras/PI3K/AKT signaling axis in human cancerous cell lines 
[13, 17, 18]. Several studies show interplay between inflammatory and oncogenic pathways [19, 
20]. However, there is no study investigating the regulatory effect of RGS on inflammatory-
associated diseases such as colitis. We have therefore, 1) integrated systems and molecular 
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biology approaches to explore a proteome-level dataset of the normal wound healing process and 
compared the deregulated proteins and the genome-wide expression changes that are induced 
by chemicals and drugs, and based on the observation that PI3K-AKT inhibitors affect all aspects 
of wound healing, 2) assessed the therapeutic efficacy of RGS against colitis and 3) examined 
the regulatory role of PI3K/AKT/NF-κB signaling axis in the protective effect of RGS on colitis 
pathological symptoms. Our results demonstrate that RGS potently attenuates clinical colitis 
symptoms, including disease activity index, histopathological score, and inflammation. We also 
showed that RGS decreases two main pathological symptoms of colitis, inflammation and fibrosis, 
by inhibition of downstream PI3K/AKT pro-fibrotic and pro-inflammatory target genes. Our data 
emphasize the therapeutic potency of this novel pharmacological inhibitor in attenuating colitis-
associated pathological symptoms. 
 
2. Materials and Methods  
 
2.1. Reagents 
Dextran sulfate sodium (DSS-40kD) and RGS were purchased from Cayman Chemical 
Company (Ann Arbor, MI). Rabbit anti-cyclin D1, anti-phospho-p65/RelA (Ser-536), anti-PI3K 
(p110α), phospho-AKT (Thr-308), and secondary antibodies were purchased from Cell Signaling 
Technology Inc. (Beverly, MA). 
 
2.2. Bioinformatics pipeline 
Based on recently published manuscript [21], “The Human Proteome Atlas” was used to 
extract the shared proteins between pulmonary and colonic tissues. To identify the proteins with 
significant changes between different stages of wound healing on days 3, 14 and 28, the 
expression value of proteins between days 3, 14 and 28 was subtracted from day 56 (complete 
resolution of injury). Proteins with at least +1 difference in value indicate the genes that are up-
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regulated at each step, and further down regulated in the resolution phase of injury. These up-
regulated proteins were submitted to BinGO app in Cytoscape to enrich biological processes 
associated with each time-point (adjusted p-value<0.05). The Enrichr web tool 
(http://amp.pharm.mssm.edu/Enrichr/) was used to identify chemicals that reversed the 
expression of proteins in the selected biological processes. iLINCs database was used to extract 
the genome-wide signature induced by RGS (Signature ID: CTRS_414). The threshold for 
identifying significantly altered drugs was set as 0<Fold change<1 and adjusted p-value <0.05. 
 
2.3. Animals  
Eight-week-old C57BL/6 male mice were purchased from the Pasteur institute of Iran 
(Tehran, Iran) and maintained according to the Institutional Animal Care Guidelines. The mice 
were housed under a 12h light/dark cycle, at room temperature (22-25°C) with free access to food 
and water ad libitum. All animal experiments were performed according to the guidelines for Care 
and Use of Laboratory Animals approved by Mashhad University of Medical Sciences. 
 
2.4. Murine colitis model and experimental protocol 
Experimental colitis was induced by administration of 1% (w/v) DSS in drinking water for 
7 days. RGS was dissolved in sterile water and administrated intraperitoneally (i.p.). Eighteen 
C57BL/6 mice were randomly divided into three groups (n= 6 for each group). The control group 
received normal drinking water for 10 days. The DSS group received 1% DSS in drinking water 
for 7 days and then received only drinking water for the next 3 days. The DSS-RGS group first 
received DSS 1% (w/v) for 7 days, followed by RGS (200 mg/kg/day) i.p. for 7 days from day 3 
until the end of the experimental period [22]. This is a well-established animal model that mimics 
the clinical and histological features of IBDs that can be validated for translation of mouse data to 
humans [23-25]. A schematic representation of experimental procedure is presented in Fig. 1B. 
During the experimental period, the animals were observed daily and evaluated for disease 
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activity index criteria (DAI) (Table 1). The loss of >20% in total body weight was use to define a 
humane endpoint for the study animals. At the end of experiments, blood samples were obtained 
and stored at -80 °C until analysis. Colonic tissues were collected and washed with cold normal 
saline and placed into 10% formalin or frozen in liquid nitrogen for further analysis.  
 
2.5. Histopathological evaluation of colons 
To score colorectal tissue damage, the formalin fixed colonic tissues were embedded in 
paraffin, sectioned and stained with haematoxylin-eosin (H&E) and Masson’s trichrome. 
Following light microscopy analysis, stained tissues were scored according to standard 
histopathological criteria presented in Table 2[4].   
 
2.6. Measurement of malondialdehyde (MDA) 
To further investigate the anti-oxidant activity of RGS, the MDA level was measured in 
colon tissue homogenates. briefly, 1 ml of 10% (weigh tissue/ volume of saline) tissue 
homogenates were mixed with 2 mL of thiobarbituric acid (TBA), Trichloroacetic acid (TCA), and 
HCL solution in boiling water for 45 minutes and centrifuged for 10 minutes. Next, the absorbance 
at 535 nm was read and the MDA level was measured by C (M) = A ⁄1.65×105 [10].     
 
2.7. Measurement of total thiol groups (SH) 
To further explore the anti-oxidant role of RGS, the total thiol group was estimated by 
DTNB (Di-Tio nitro benzoic acid) reagent. DTNB reacts with SH groups and produces the color 
yellow complex. In this line, 1ml of Tris-EDTA buffer (pH = 8.6) was added to tissue homogenate 
and the specimen absorbance read at 412 nm against Tris-EDTA buffer alone (A1). Next, 20 μl 
of DTNB reagents were added to this solution and incubated at room temperature for 15 minutes. 
Then, the sample absorbance was measured again (A2). The absorbance of DTNB reagent was 
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used as a blank (B). Total thiol concentration (mM) was calculated by SH (mM) = (A2-A1-B) × 
1.07 / (0.05 × 13.6) [26]. 
 
2.8. Measurement of catalase (CAT) activity 
The catalase (CAT) enzyme activity was detected exactly as described previously by Aebi 
et al. The rational of this method was based on the hydrolyzation of H2O2 in phosphate buffer, pH 
7.0, and reducing absorbance at 240 nm. The enzyme activity can be estimated by the conversion 
of H2O2 to H2O and O2 in 1 min under standard situation [27, 28]. For evaluation of the CAT 
enzyme activity, the tissue samples were minced in small pieces and washed in twice-distilled 
water. Next, 1 g of tissues were homogenized in 5 ml of phosphate buffer solution. The 
homogenized samples were centrifuged and the supernatants were employed for evaluating CAT 
enzyme activity. 
 
2.9. Real-time PCR 
            The mRNA expression levels of inflammatory, fibrotic and proliferative genes were 
evaluated using specific primers obtained from Macrogene Co. (Seoul, Korea) by real-time 
quantitative PCR (Table 3) as described [29]. Total RNA was extracted from frozen colon tissues 
of mice using the RNeasy Mini kit purchased from Qiagen Inc. (Hilden, Germany). Next, 1 μg of 
extracted RNA was reversed transcribed into complementary cDNA by a cDNA Reverse 
Transcription Kit according to the manufacturer’s protocol (TaKaRa Bio, Shiga, Japan) and 
equivalent amounts of cDNA were used for the quantitative real-time PCR reactions using the 
Ampliqon SYBR Green PCR Master Mix. The expression levels were normalized to the Gapdh 
as housekeeping control gene. The ΔCT was calculated by subtracting the CT value of the Gapdh 
reference gene from that of each target gene. Results were expressed as a relative fold difference 




2.10. Western blotting 
Western blotting was performed as described [20, 30]. Briefly, total protein of colon tissues 
were extracted using RIPA lysis buffer (25 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 
0.5% Triton X100, 0.5% SDS) containing a protease and phosphatase inhibitor cocktail (Thermo 
Scientific Pierce, Rockford, IL). The lysate was centrifuged at 13,000g for 10 min at 4°C and the 
supernatant was collected. The protein concentration was measured using the Pierce BCA protein 
assay kit (Thermo Scientific, Rockford, IL). Protein samples (30 microgram) were subjected to 
electerophoresis and transferred to polyvinylidene difluoride (PVDF) membranes (Immobilon-P, 
Millipore, Bedford, MA). Following a blocking step (with non-fat dry milk 5% in TBS containing 
0.1% tween 20), the membranes were washed with TBS three times and incubated over night 
with primary (1:1000) and secondary (1:3000) antibodies. The membrane was then washed with 
TBS three times and incubated in Super-Signal West Femto Chemiluminescent Substrate 
(Thermo Scientific, Rockford, IL).   
 
2.11. Statistical analysis 
One-way analysis of variance (ANOVA) and the Wilcoxon Mann–Whitney tests were used 
for non-parametrically distributed samples. Results were presented as means ± SEM. Values 
obtained from three independent experiments. Differences were considered to be statistically 
significant at P < 0.05. For statistical enrichments in the bioinformatics pipeline, False Discovery 
Rate (FDR) was considered significant at P <0.05. 
 
3. Results 
3.1. PI3K-AKT inhibitors are effective agents against UC 
Recently Schiller et al. provided in vivo time-resolved proteome profiling for the sequential 
steps in a normal wound healing process when an injury with Bleomycin was induced in the in 
lung epithelium [21]. They analyzed the whole tissue proteome and provided the list of protein 
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whose expressions were altered in each step of transition from inflammatory to resolving phase 
of the injury. Since 1) colitis is an inflammatory condition with impaired healing and resolving 
process, and 2) such high throughput data could not be found in the literature for colonic tissue, 
it was assumed that genes commonly expressed in lung and colon epithelia would have similar 
dynamics in a normally resolving injury in UC. There are several publications that highlight the 
similarities of intestine and lung tissues in terms of function and diseases. For instance, 1) 
intestine and lung are both originated from foregut at embryonic stage so both have the same 
rigin (gut-lung axis). 2) Both tissues form the mucos-based epithelial barriers that are exposed to 
have similar inflammatory components such as common mucosal immune system. 3) Correlation 
has been observed in pulmonary involvement in patients with inflammatory bowel diseases [42-
44]. To identify a drug that can reverse the expression of up-regulated proteins in each phase [12] 
we used “The Human Proteome Atlas” to extract the shared proteins between lung and colon 
tissue. As shown in Fig. 2A, similar to lung data, the extracted proteins for the colon also showed 
4 clusters representing 3 distinct phases (Inflammation, fibrogenesis and remodeling) before the 
injury is fully resolved.  
Accordingly, we observed different biological processes involved in each step (Fig. 2B). 
Moreover, similar to the whole dataset in the lung injury, injury is initiated by a cascade of 
inflammatory responses in the colon proteome subset which is followed by the intensive protein 
metabolic alterations leading to fibrogenesis. Then, the healing response is initiated by metabolic 
alterations involving oxidation-reduction. Finally, by down-regulation of cellular respiration 
processes, cell adhesion-related proteins are up-regulated to fully resolve the injury. These results 
suggest that if the objective is to treat colitis and its consequences, we should first overcome the 
inflammatory/fibrogenesis phase of the disease, and then allow healing to occur; we should also 
pass the ECM remodeling/proliferation phase. To identify a drug that can regulate these distinct 
stages, we extracted the up-regulated genes in each of the 3 phases before resolution and tried 
to find a drug down-regulating the proteins of each phase distinctly using Enrichr web-based 
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enrichment tool (Fig. 3). We observed that PI3K and AKT inhibitors were among the top-five 
chemicals that reversed the expression of up-regulated proteins in all phases of response to 
injury.  
After selecting the shared genes that are expressed in colon and lung (n=2466 proteins), 
the dynamics of the protein changes were determined according to the proteomic study data. The 
expression status of proteins on day 56 was assumed as the reference for full resolution of injury. 
Thus for each phase, the proteins whose expression was higher than day 56 were selected that 
included the following numbers:  
Day 3: n=15 proteins, Day 14: n= 180 proteins, day 28: = 73 proteins. The differentially 
expressed proteins in each of the mentioned days compared to day 56 were then submitted to 
BinGo (Fig. 2B) and EnrichR (Fig. 3A) for further analyses. To identify a drug that can reverse the 
expression of up-regulated proteins, we observed that PI3K-AKT inhibitors were a class of drug 
that affected the expression of up-regulated proteins in each of the wound healing phases 
implying that over-actiovation of this pathway does not allow the wound healing process to 
terminate. It has been shown that RGS could inhibit PI3K/AKT in solid tumors (17, 18. 45). 
Moreover, RGS is already under phase 3 clinical trials for CML that if approved by FDA, will have 
higher chance in translational repurposing for UC treatment. So we used the RGS gene 
expression signature to identify genes that are mutually altered by wound healing and RGS (Fig. 
3B and Supplementary file.1). These results could support the rationale that inhibition of the 
PI3/AKT signaling pathway may be a promising therapeutic approach in treatment of UC. 
3.2. Rigosertib attenuates clinical symptoms of colitis 
To validate our in-silico findings, we assessed the efficacy of RGS in DSS-induced colitis 
model in mouse (n=6 in each group). Our findings showed that all mice with experimentally-
induced colitis that were not treated with RGS developed clinical features of colitis including 
bloody stool, diarrhea, weight loss, and a high disease activity index (DAI). RGS treatment was 
associated with a significant reduction in body weight loss in DSS-induced colitis mice, compared 
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to RGS-untreated colitis group (Fig. 4A). RGS treatment attenuated the DAI in the mice with DSS-
induced colitis (Fig. 4B) supporting a protective effect of this pharmacological inhibitor on features 
of colitis. To further investigate the therapeutic potency of RGS against colitis, the length of colons 
of mice were compared between the different groups. As is shown in Fig. 4C, RGS inhibited DSS-
induced colon shortening in colitis mice. Furthermore, RGS improved colon weight to colon length 
ratio, a marker of inflammation and tissue edema (Fig. 4D). These results support the ameliorative 
effects of RGS on pathological symptoms in colitis. 
  
3.3.  Rigosertib decreases colorectal tissue damage in colitis 
We studied the effect of RGS on colon tissue damage including tissue inflammation, 
mucosal damage and crypt loss between RGS-treated and untreated colitis mice. Our results 
showed that RGS had a potent protective effect on colon histological score (Fig. 5A) including 
inflammation score (Fig. 5B), mucosal damage (Fig. 5C) and crypt loss (Fig. 5D) in the DSS-
induced colitis mice (n=6 in each group). Consistent with these findings, pathological changes 
were more severe in DSS group, as evidenced by increased sub-mucosal edema, morphological 
damage and greater inflammatory cell infiltration. However, in the RGS-treated mice, colon tissue 
structure was partially protected and inflammatory symptoms were decreased (Fig. 5 E), 
suggesting that RGS significantly improves clinical and histological features induced by DSS in 
colitis. 
 
3.4. Anti-inflammatory role of Rigosertib in colitis  
Next, we studied the regulatory role of RGS in colitis-associated inflammation in mouse 
tissue and serum. Compared to control colitis mice, treatment of colitis mice with RGS abrogated 
the inhibitory effect of DSS on total thiol concentration and catalase activity, suggesting that RGS 
displays anti-oxidant activity in colitis (n=6 in each group) (Fig. 6A and B). Consistent with these 
findings, RGS reduced levels of malonyl dialdehyde (MDA) and high-sensitive C reactive protein 
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(hs-CRP), in tissue homogenate and blood samples of DSS-induced colitis mice, respectively 
(Fig. 6C and D). Moreover, comparison of pro-inflammatory genes expression levels between 
RGS-treated and untreated colitis mice showed that RGS significantly down-regulated the 
expression of interleukin-1𝛽 (Il-1𝛽), tumor necrosis factor alpha (Tnf-α), Interferon gamma (Inf-γ), 
and macrophage chemotactic protein-1 (Mcp-1) in colitis tissue (Fig. 6E). These results suggest 
that protective effects of RGS against colitis were at least partially mediated by induction of anti-
oxidant and anti-inflammatory responses. 
 
3.5. Anti-fibrotic effects of Rigosertib in colitis mice 
Colonic fibrosis is characterized by excessive collagen deposition and over-expression of 
fibrogenic factors which is a key step in the pathogenesis of colitis [31]. To investigate the 
modulatory effect of RGS on collagen deposition and fibrosis, colon tissues of different groups 
were stained with Masson’s trichrome. Histopathological staining results showed that RGS 
significantly decreases deposition of collagen in colon tissues of DSS-induced colitis mice, 
supporting the anti-fibrotic activity of this inhibitor in colitis (Fig. 7A). In agreement with these 
results, mRNA expression of pro-fibrotic genes including collagen type 1 alpha 1 (Col1a1), 
collagen type 1 alpha 2 (Col1a2), and alpha-actin-2 (Acta 2) were down-regulated in the colon 
tissue homogenates of RGS-treated colitis mice, in comparison to the colitis control group (n=6 
in each group) (Fig. 7B). These results clearly suggest that RGS has novel therapeutic properties 
against colitis with clinically translational potential of inhibiting key pathological colitis responses 
of inflammation and fibrosis in human patients.  
 
3.6. Inhibitory effect of Rigosertib on cell proliferation in colonic tissue 
It has been shown that UC patients are at higher risk for developing colorectal cancer [8]. 
Since RGS is an inhibitor of oncogenic Ras/PI3K/AKT signaling axis, we investigated effect of 
this inhibitor on colitis-associated colorectal cancer by comparing activation or expression level 
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of proliferative regulatory pathways, including PI3K/AKT and NF-kB in colon tissue homogenates 
between different groups. As shown in Fig. 8A, treatment of colitis mice with RGS potently down-
regulates expression of nuclear factor-kB (RelA), as well as AKT. Regulatory effect of RGS on 
cyclin D1 expression, a down-stream target gene of AKT pathway, is elicited at the post-
transcriptional level (Fig. 8A and B). Consistently, RGS decreased phosphorylation and activation 
of AKT and NF-kB (p65/RelA) signaling pathways in colitis tissue samples (Fig. 8B and C), 
demonstrating protective signaling effects of RGS against colitis-induced colon cancer.  
 
4. Discussion 
In this study, we have shown for the first time that RGS significantly attenuates colitis-
associated intestinal fibrosis and inflammation by modulating PI3K/AKT and NF-κB signaling 
pathways in a colitis mice model. Moreover, it is noteworthy that RGS potently improved disease 
activity index including body weight loss, diarrhea, rectal bleeding and colonic length, as well as 
colon histopathological score by eliciting anti-oxidative and anti-inflammatory responses in DSS-
induced colitis mice model.  
During colon inflammation, the oxidant/anti-oxidant balance is perturbed leading to 
disruption of the epithelial cell membrane which is considered as one of the initial events during 
the onset of IBDs. This membrane disruption causes macrophage, neutrophil and lymphocyte 
infiltration into the mucosal and sub-mucosal areas which exacerbates inflammatory responses 
by producing inflammatory cytokines, such as TNF-α, MCP-1, IFN-γ and ILs accompanied by up-
regulation of NF-kB pro-inflammatory signaling pathway [32-34]. In this line, Peng et al. 
demonstrated that the expression of proinflammatory cytokines including TNF-α, IFN-γ and IL-1β 
was significantly induced by DSS in colitis mice model. Additionally, further studies in DSS 
induced colitis indicated that elevated macrophage and neutrophil infiltration (as a main resource 
of inflammatory cytokines) are related to progression of inflammation and mucosal damage. Their 
results indicated that inhibition of PI3K/AKT signaling suppresses leukocyte infiltration and 
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inflammatory responses in DSS induced colitis mice trough reducing  expression of inflammatory 
cytokines or upregulating anti-inflammatory cytokines[35]. 
Consistent with these findings, our results revealed that RGS significantly decreases 
inflammation and regulates oxidant/anti-oxidant balance by down-regulation of inflammatory 
cytokines, increasing catalase enzyme activity and regulating thiol and MDA concentrations.  
Previous studies have suggested that pro-inflammatory pathways, such as NF-kB, induce 
tumorigenesis by up-regulating inflammatory cytokines including TNF-α and IL-1β [36, 37]. 
Furthermore, the PI3K/AKT signaling axis induces phosphorylation of NF-kB signaling through 
degradation of inhibitor of κB (IκB) [38, 39]. Based on these findings, we investigated the effect of 
RGS, a PI3K inhibitor, on NF-kB in DSS-induced colitis. Our results showed that RGS down-
regulates cyclin D1 expression in colitis mice. Moreover, RGS suppresses NF-kB signaling 
pathway via down-regulation of Nf-kb (RelA) gene expression and de-phosphorylation and 
inactivation of p-65/RelA subunit in colitis mice.  
Consistent with the regulatory effects of RGS on inflammation, we studied effect of this 
pharmacological inhibitor on colitis-associated fibrosis. Our results indicate that RGS treatment 
suppresses the expression of pro-fibrotic factors, which is in accordance with other studies, as it 
clearly suggests an association between inflammation and fibrosis [40, 41]. 
The current study explores a novel therapeutic role of RGS against colitis through 
inhibition of PI3K/AKT and NF-κB signaling pathways in colitis mice. The inhibitory role of RGS 
on proliferative signaling pathways including PI3K/AKT as well as down-stream target genes such 
as cyclin D1 is clinically relevant to the association between colitis as a risk factor for colon cancer 
[42]. The therapeutic potency of RGS against DSS-induced colon tissue degradation is mediated 
by suppression of inflammation and fibrosis not necessarily by regulating cell proliferation. But 
decrease in cell proliferation during tissue regeneration may postpone colitis treatment in patients. 
Further investigation should be performed to evaluate side effects of rigosertib administration in 
other cellular, animal and clinical studies in colitis patients. Further investigation into the 
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mechanisms involved in the protective effects of RGS will advance our knowledge about the exact 
molecular mechanism of the protective signaling functions of RGS against colitis pathogenesis, 
colitis-associated colorectal cancer, and other pro-inflammatory and pro-fibrotic disorders for a 
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Figure 1. Schematic representation of bioinformatics pipeline and experimental design of 
the study (A) A proteome level dataset containing time-resolved healing from lung injury was 
used as the initial source of high-throughput data. The Human Proteome Atlas was used to extract 
shared genes between colon and lung tissue. BinGO, a Cytoscape plugin was used to extract 
relevant biological processes involved in each step of wound healing. Enrichr and iLINCS tools 
and databases were used to identify and validate a drug affecting each step of normal wound 
healing, respectively. (B) Schematic representation of murine colitis model and experimental 
protocol. (C) Experimental validation steps to confirm the effect of identified drug on treatment of 
colitis.  
 
Figure 2. Dynamic changes of proteins and biological processes involved in healing 
process of colon (A) z-score intensities of proteins that are commonly expressed in lung and 
colon tissue in different steps of wound healing. (B) The biological processes significantly 
enriched for proteins expressed in colon and altered in wound healing process. Adjusted p-value 
<0.05 was considered significant.  
 
Figure 3.  Drugs that reverse the expression of up-regulated proteins in each phase of 
normal healing from injury (A) The LINCS L1000 Down module within Enrichr web-based 
enrichment tool was used to identify drugs that reverse the expression of up-regulated proteins in 
each phase of wound healing. (B) Gene signature of Rigosertib was extracted from iLINCS 
database and was used to identify shared proteins in the wound healing process that are altered 




Figure 4. Protective effects of RGS on colitis clinical symptoms (A) RGS (200 mg/kg/day;ip) 
decreases DSS-induced body weight loss in colitis mice (n=6 in each group). (B) Disease activity 
index score was compared between control group, RGS-untreated- and -treated colitis mice. (C). 
The same as panel B except that the inhibitory effect of RGS on DSS-induced colon shortening 
was measured. (D) The same as panel C except that colon weight to colon length ratio was 
measured. Each experiment was performed in triplicate.*p<0.05; **p<0.01 
 
Figure 5. RGS attenuates colon tissue damage in colitis mice. (A) Colon damage histological 
score is compared between different groups (n=6 in each group). (B) RGS abrogates DSS-
induced inflammation in colitis mice. (C) The same as panel B except that mucosal damage score 
was measured between groups. (D) The same as panel B except that the protective effect of RGS 
on DSS-induced crypt loss was investigated. (E) Hematoxylin and eosin (H&E)-stained sections 
of colons from indicated groups of mice showing representative histopathological damage 
induced by DSS on day 10. Each experiment was performed in triplicate. *p<0.05; ***p<0.001. 
 
Figure 6. Anti-oxidant and anti-inflammatory responses of RGS in colitis. Colitis mice were 
treated with or without RGS and (A) Total thiol concentration, (B) catalase activity, and (C) MDA 
level were measured in colon tissue homogenates (n=6 in each group). (D) Serum concentration 
of high-sensitive C reactive protein (hs-CRP) was compared in the serum samples between 
groups. (E) RGS significantly decreased expression level of pro-inflammatory genes in colitis 
mice, compared to untreated colitis group. Each experiment was performed in triplicate. *p<0.05; 
**p<0.01; ***p<0.001. 
 
Figure 7. RGS attenuates fibrosis in colitis. (A) Histopathological staining with Masson’s 
trichrome showed decreased collagen deposition (blue stained, black arrows) in the RGS-
treated group compared to DSS group (n=6 in each group). (B) Expression levels of pro-fibrotic 
22 
 
genes are suppressed in RGS-treated colitis group. Each experiment was performed in triplicate. 
**p<0.01. 
 
Figure 8. RGS suppresses proliferative and inflammatory signaling pathways in colitis.  
 (A) RGS significantly down-regulates mRNA levels of Akt, Nf-kb (RelA), and Cyclin D1, compared 
to un-treated colitis group (n=6 in each group). (B) Colon tissues were homogenized and 
expression level of PI3K and cyclin D1 as well as phosphorylation levels of AKT and p-65 were 
evaluated between different groups. (C) Quantitative analysis of PI3K and cyclin D1 protein 










Table 2. Colorectal tissue damage was scored according to histopathological criteria. 
 
 
Table 3. qPCR primer sequences 
 




















Nf-kb (RelA) Mouse 
Forward CCAAGGACATGACTGCTCAA 
Reverse AGACGCTGCCTCTGAAGTTT 
Tnf-α Mouse 
Forward AGGCTGTCGCTACATCACTG 
Reverse CTCTCAATGACCCGTAGGGC 
Il-1β Mouse 
Forward GACTTCACCATGGAATCCGT 
Reverse TGCTCATTCACGAAAAGGGA 
Ifn-γ Mouse 
Forward TGGCTGTTTCTGGCTGTTAC 
Reverse CTCTTTTCTTCCACATCTATGCC 
Mcp-1 Mouse 
Forward GTGAAGTTGACCCGTAAATCTGA 
Reverse ACTAGTTCACTGTCACACTGGT 
 
 
